Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Harvard Business School
Chinese Patent Office

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,225,474

« Back to Dashboard

Which drugs does patent 6,225,474 protect, and when does it expire?

Patent 6,225,474 protects ULORIC and is included in one NDA. There has been one Paragraph IV challenge on Uloric.

This patent has fifty-five patent family members in thirty-four countries.

Summary for Patent: 6,225,474

Title: Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
Abstract:The present invention provides a technique of selectively producing a desired polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid. The present invention also provides a method of producing various polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, which comprises crystallizing under the conditions defined by a specific temperature and a composition of a mixed solvent of methanol and water, and polymorphs obtained by the method. The present invention further provides a method of producing the other polymorphs or amorphous compounds by drying a specific polymorph under a reduced pressure with heating, and the other polymorphs or amorphous compounds obtained by the method.
Inventor(s): Matsumoto; Koichi (Iwakuni, JP), Watanabe; Kenzo (Iwakuni, JP), Hiramatsu; Toshiyuki (Iwakuni, JP), Kitamura; Mitsutaka (Higashi-Hiroshima, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:09/485,861
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms UsaULORICfebuxostatTABLET;ORAL021856-001Feb 13, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaULORICfebuxostatTABLET;ORAL021856-002Feb 13, 2009RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,225,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-173079Jun 19, 1998
PCT Information
PCT FiledJune 18, 1999PCT Application Number:PCT/JP99/03258
PCT Publication Date:December 23, 1999PCT Publication Number: WO99/65885

International Patent Family for Patent: 6,225,474

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1020454► Subscribe
Poland200710► Subscribe
Poland338780► Subscribe
New Zealand503326► Subscribe
Norway321308► Subscribe
Norway20000789► Subscribe
Luxembourg91682► Subscribe
South Korea100511183► Subscribe
Japan3547707► Subscribe
Iceland9022► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Federal Trade Commission
Cantor Fitzgerald
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: